3,5-Diiodo-L-thyronine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581054

CAS#: 1041-01-6

Description: 3,5-Diiodo-L-thyronine, Iodinated thyronine hormone. regulating gene activity affecting processes such as homeostasis, lipid metabolism and insulin resistance.

Chemical Structure

img
3,5-Diiodo-L-thyronine
CAS# 1041-01-6
Instruction

Theoretical Analysis

MedKoo Cat#: 581054
Name: 3,5-Diiodo-L-thyronine
CAS#: 1041-01-6
Chemical Formula: C15H13I2NO4
Exact Mass: 524.89
Molecular Weight: 525.080
Elemental Analysis: C, 34.31; H, 2.50; I, 48.34; N, 2.67; O, 12.19

Price and Availability

Size Price Availability Quantity
1g USD 350 2 Weeks
5g USD 750 2 Weeks
Bulk inquiry

Synonym: 3,5-Diiodo-L-thyronine; (S)-2-amino-3-(4-(4-hydroxyphenoxy)-3,5-diiodophenyl)propanoic acid; 3,5-T2; NSC 90469.

IUPAC/Chemical Name: 3,5-T2; NSC 90469; (2S)-2-Amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid

InChi Key: ZHSOTLOTTDYIIK-ZDUSSCGKSA-N

InChi Code: InChI=1S/C15H13I2NO4/c16-11-5-8(7-13(18)15(20)21)6-12(17)14(11)22-10-3-1-9(19)2-4-10/h1-6,13,19H,7,18H2,(H,20,21)/t13-/m0/s1

SMILES Code: O=C(O)[C@@H](N)CC1=CC(I)=C(OC2=CC=C(O)C=C2)C(I)=C1

Appearance: Solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 525.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Senese R, Cioffi F, de Lange P, Leanza C, Iannucci LF, Silvestri E, Moreno M, Lombardi A, Goglia F, Lanni A. Both 3,5-Diiodo-L-Thyronine and 3,5,3'-Triiodo-L-Thyronine Prevent Short-term Hepatic Lipid Accumulation via Distinct Mechanisms in Rats Being Fed a High-Fat Diet. Front Physiol. 2017 Sep 14;8:706. doi: 10.3389/fphys.2017.00706. eCollection 2017. PubMed PMID: 28959215; PubMed Central PMCID: PMC5603695.

2: Fallahi P, Ferrari SM, Santini E, Camastra S, Frenzilli G, Puccini M, Goglia F, Lanni A, Marchetti P, Antonelli A. Both 3,5-diiodo-L-thyronine (T2) and T3 modulate glucose-induced insulin secretion. J Biol Regul Homeost Agents. 2017 Apr-Jun;31(2):503-508. PubMed PMID: 28685559.

3: Moreno M, Giacco A, Di Munno C, Goglia F. Direct and rapid effects of 3,5-diiodo-L-thyronine (T2). Mol Cell Endocrinol. 2017 Dec 15;458:121-126. doi: 10.1016/j.mce.2017.02.012. Epub 2017 Feb 10. PubMed PMID: 28192176.

4: Moreno M, Silvestri E, Coppola M, Goldberg IJ, Huang LS, Salzano AM, D'Angelo F, Ehrenkranz JR, Goglia F. 3,5,3'-Triiodo-L-Thyronine- and 3,5-Diiodo-L-Thyronine- Affected Metabolic Pathways in Liver of LDL Receptor Deficient Mice. Front Physiol. 2016 Nov 17;7:545. eCollection 2016. PubMed PMID: 27909409; PubMed Central PMCID: PMC5112267.

5: Cavallo A, Taurino F, Damiano F, Siculella L, Sardanelli AM, Gnoni A. Acute administration of 3,5-diiodo-L-thyronine to hypothyroid rats stimulates bioenergetic parameters in liver mitochondria. J Bioenerg Biomembr. 2016 Oct;48(5):521-529. Epub 2016 Nov 17. PubMed PMID: 27854029.

6: Coppola M, Cioffi F, Moreno M, Goglia F, Silvestri E. 3,5-diiodo-L-thyronine: A Possible Pharmacological Agent? Curr Drug Deliv. 2016;13(3):330-8. Review. PubMed PMID: 26593437.

7: Vatner DF, Snikeris J, Popov V, Perry RJ, Rahimi Y, Samuel VT. 3,5 Diiodo-L-Thyronine (T2) Does Not Prevent Hepatic Steatosis or Insulin Resistance in Fat-Fed Sprague Dawley Rats. PLoS One. 2015 Oct 20;10(10):e0140837. doi: 10.1371/journal.pone.0140837. eCollection 2015. PubMed PMID: 26485433; PubMed Central PMCID: PMC4618341.

8: Lombardi A, Senese R, De Matteis R, Busiello RA, Cioffi F, Goglia F, Lanni A. 3,5-Diiodo-L-thyronine activates brown adipose tissue thermogenesis in hypothyroid rats. PLoS One. 2015 Feb 6;10(2):e0116498. doi: 10.1371/journal.pone.0116498. eCollection 2015. PubMed PMID: 25658324; PubMed Central PMCID: PMC4319745.

9: Silvestri E, Coppola M, Cioffi F, Goglia F. Proteomic approaches for the study of tissue specific effects of 3,5,3'-triiodo-L-thyronine and 3,5-diiodo-L-thyronine in conditions of altered energy metabolism. Front Physiol. 2014 Dec 17;5:491. doi: 10.3389/fphys.2014.00491. eCollection 2014. Review. PubMed PMID: 25566089; PubMed Central PMCID: PMC4269122.

10: Hernandez A. 3,5-diiodo-L-thyronine (t2) in dietary supplements: what are the physiological effects? Endocrinology. 2015 Jan;156(1):5-7. doi: 10.1210/en.2014-1933. PubMed PMID: 25526549; PubMed Central PMCID: PMC4272398.

11: Jonas W, Lietzow J, Wohlgemuth F, Hoefig CS, Wiedmer P, Schweizer U, Köhrle J, Schürmann A. 3,5-Diiodo-L-thyronine (3,5-t2) exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice. Endocrinology. 2015 Jan;156(1):389-99. doi: 10.1210/en.2014-1604. PubMed PMID: 25322465; PubMed Central PMCID: PMC4272399.

12: Grasselli E, Voci A, Canesi L, Salis A, Damonte G, Compalati AD, Goglia F, Gallo G, Vergani L. 3,5-diiodo-L-thyronine modifies the lipid droplet composition in a model of hepatosteatosis. Cell Physiol Biochem. 2014;33(2):344-56. doi: 10.1159/000356674. Epub 2014 Feb 5. PubMed PMID: 24525903.

13: Markova N, Chernopiatko A, Schroeter CA, Malin D, Kubatiev A, Bachurin S, Costa-Nunes J, Steinbusch HM, Strekalova T. Hippocampal gene expression of deiodinases 2 and 3 and effects of 3,5-diiodo-L-thyronine T2 in mouse depression paradigms. Biomed Res Int. 2013;2013:565218. doi: 10.1155/2013/565218. Epub 2013 Dec 10. PubMed PMID: 24386638; PubMed Central PMCID: PMC3872397.

14: Rochira A, Damiano F, Marsigliante S, Gnoni GV, Siculella L. 3,5-Diiodo-l-thyronine induces SREBP-1 proteolytic cleavage block and apoptosis in human hepatoma (Hepg2) cells. Biochim Biophys Acta. 2013 Dec;1831(12):1679-89. doi: 10.1016/j.bbalip.2013.08.003. Epub 2013 Aug 13. PubMed PMID: 23948263.

15: Shang G, Gao P, Zhao Z, Chen Q, Jiang T, Zhang N, Li H. 3,5-Diiodo-l-thyronine ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats. Biochim Biophys Acta. 2013 May;1832(5):674-84. doi: 10.1016/j.bbadis.2013.01.023. Epub 2013 Feb 8. PubMed PMID: 23416120.

16: Cavallo A, Priore P, Gnoni GV, Papa S, Zanotti F, Gnoni A. 3,5-Diiodo-L-thyronine administration to hypothyroid rats rapidly enhances fatty acid oxidation rate and bioenergetic parameters in liver cells. PLoS One. 2013;8(1):e52328. doi: 10.1371/journal.pone.0052328. Epub 2013 Jan 4. PubMed PMID: 23308110; PubMed Central PMCID: PMC3537720.

17: Antonelli A, Fallahi P, Ferrari SM, Di Domenicantonio A, Moreno M, Lanni A, Goglia F. 3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. J Biol Regul Homeost Agents. 2011 Oct-Dec;25(4):655-60. PubMed PMID: 22217997.

18: Grasselli E, Voci A, Demori I, Canesi L, De Matteis R, Goglia F, Lanni A, Gallo G, Vergani L. 3,5-Diiodo-L-thyronine modulates the expression of genes of lipid metabolism in a rat model of fatty liver. J Endocrinol. 2012 Feb;212(2):149-58. doi: 10.1530/JOE-11-0288. Epub 2011 Nov 22. PubMed PMID: 22107956.

19: de Lange P, Cioffi F, Senese R, Moreno M, Lombardi A, Silvestri E, De Matteis R, Lionetti L, Mollica MP, Goglia F, Lanni A. Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats. Diabetes. 2011 Nov;60(11):2730-9. doi: 10.2337/db11-0207. Epub 2011 Sep 16. PubMed PMID: 21926273; PubMed Central PMCID: PMC3198093.

20: Cavallo A, Gnoni A, Conte E, Siculella L, Zanotti F, Papa S, Gnoni GV. 3,5-diiodo-L-thyronine increases FoF1-ATP synthase activity and cardiolipin level in liver mitochondria of hypothyroid rats. J Bioenerg Biomembr. 2011 Aug;43(4):349-57. doi: 10.1007/s10863-011-9366-3. Epub 2011 Jul 8. PubMed PMID: 21739248.